Search
forLearn
5 / 5 resultslearn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn Estradiol
an estrogen promoting hair regrowth more commonly used in women
learn Alfatradiol
a synthetic estrogen used topically as an anti-androgen
learn Dutasteride
Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity
Research
5 / 1000+ resultsresearch The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
![Androgen receptor: A promising therapeutic target in breast cancer](/images/research/d87f276d-7635-48af-852d-511a21db081c/small/17725.jpg)
research Androgen receptor: A promising therapeutic target in breast cancer
The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
![Aldosterone- and cortisol-cosecreting adrenal adenoma, ovarian hyperthecosis and breast cancer](/images/research/5be5ee4c-68ba-4176-9ed1-31087ba2ba7d/small/13307.jpg)
research Aldosterone- and cortisol-cosecreting adrenal adenoma, ovarian hyperthecosis and breast cancer
The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
![202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter](/images/research/a8a607f9-e5ed-4251-9df5-d80261ea2fa0/small/24738.jpg)
research 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
![Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer](/images/research/d0cbbdb8-d220-46a6-95c3-82dfddbc4656/small/13151.jpg)
research Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
Community Join
5 / 581 resultscommunity Just had this wild thought come into my head.
The conversation is about the debate over the existence of Post-Finasteride Syndrome (PFS) and its symptoms, with some users skeptical about PFS and others discussing side effects like erectile dysfunction and gynecomastia from hair loss treatments like finasteride. Specific treatments mentioned include finasteride, viagra, and a joke about using a popsicle stick for erectile support.
community Female, 30, PCOS diagnosis, MPB Norwood 2. Endo refuses to give anything other than Spironolactone. Feel like I’m at my wit’s end here.
A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.
community Post Finasteride Syndrome, A dangerous lie.
A user initially had side effects from finasteride, attributed them to anxiety and the nocebo effect, and after resuming the drug, experienced positive effects and now warns against misinformation about Post Finasteride Syndrome.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.